Summary
The product Parabolan 100, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number UN56362, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of trenbolone hexahydrobenzylcarbonate, with a concentration of 87.86 mg/ml, which is 12.14% lower than the labeled claim of 100 mg/ml.
The testing process began on 1 August 2022, with the sample received on 9 August 2022, and analysis completed on 12 August 2022. The sample was retested twice to ensure accuracy. While the results indicate underdosing, scrutiny of reseller-submitted samples is essential to ensure reliability. Resellers may select specific batches that meet high-quality standards, raising questions about product consistency across the broader market. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: Parabolan 100
- Active Ingredient: Trenbolone Hexahydrobenzylcarbonate
- Batch Number: UN56362
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #22622
- Testing Ordered: 1 August 2022
- Sample Received: 9 August 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 100 mg/ml (as stated on the label)
- Measured Concentration: 87.86 mg/ml
- Accuracy: 87.86% (12.14% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/22622_JAH7VF9D64Z9
Evaluation of Reseller-Submitted Testing
This analysis highlights the underdosing of the tested product, warranting careful evaluation due to its submission and funding by the reseller Opitropin.EU. Resellers often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Parabolan 100 is underdosed, with a measured concentration of 87.86 mg/ml. This result reflects potential quality control issues for this batch and underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
